J. Bártková

发表

A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.

O. Kallioniemi, J. Kononen, H. Nevanlinna, 2002, American journal of human genetics.

Expression of monoclonal antibody-defined epitopes of keratin 19 in human tumours and cultured cells.

J. Bartek, J. Bártková, J. Schneider, 1986, European journal of cancer & clinical oncology.

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

T. Ørntoft, J. Nesland, J. Bartek, 2005, Nature.

DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer

R. Harris, Emily K. Law, N. McGranahan, 2016, Genome Biology.

Immortalised breast epithelia survive prolonged DNA replication stress and return to cycle from a senescent-like state

J. Bartek, J. Bártková, A. Maya-Mendoza, 2014, Cell Death and Disease.

Differences in DNA double strand breaks repair in male germ cell types: lessons learned from a differential expression of Mdc1 and 53BP1.

J. Bartek, J. Bártková, Junjie Chen, 2007, DNA repair.

53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer

Jiri Bartek, J. Bartek, J. Bártková, 2002, Nature Cell Biology.

Lack of p19INK4d in human testicular germ-cell tumours contrasts with high expression during normal spermatogenesis

J. Bartek, J. Bártková, N. Skakkebæk, 2000, Oncogene.

Perspective: defects in cell cycle control and cancer

J. Bartek, J. Lukas, J. Bártková, 1999 .

Immunohistochemical analysis of the D-type cyclin-dependent kinases Cdk4 and Cdk6, using a series of monoclonal antibodies.

J. Bartek, J. Lukas, C. Lukas, 1999, Hybridoma.

A Requirement for Cyclin D3–Cyclin-dependent Kinase (cdk)-4 Assembly in the Cyclic Adenosine Monophosphate–dependent Proliferation of Thyrocytes

J. Bartek, J. Lukas, J. Bártková, 1998, The Journal of cell biology.

DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1

J. Bartek, J. Lukas, J. Bártková, 1994, The Journal of cell biology.

Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity

J. Bartek, J. Lukas, J. Bártková, 1995, Molecular and cellular biology.

Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16

J. Bartek, J. Lukas, G. Peters, 1995, Nature.

Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints

Dimitris Kletsas, Jiri Bartek, Frederic Tort, 2006, Nature.

Evaluation of RAD50 in familial breast cancer predisposition

Päivi Heikkilä, Jiri Bartek, Nazneen Rahman, 2006, International journal of cancer.

TRIP12 and UBR5 Suppress Spreading of Chromatin Ubiquitylation at Damaged Chromosomes

Jiri Bartek, Darren Saunders, Beate Neumann, 2014, Cell.

DNA damage-induced dynamic changes in abundance and cytosol-nuclear translocation of proteins involved in translational processes, metabolism, and autophagy

D. H. Larsen, J. Bartek, J. Lukas, 2018, Cell cycle.

J. Bartek, J. Lukas, J. Bártková, 1994, The Journal of pathology.

Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro

J. Bartek, J. Bártková, J. Kovarik, 1990, International journal of cancer.

SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair

Z. Szallasi, M. Stratton, N. Matthews, 2015, Oncogene.

Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours.

J. Bartek, J. Lukas, J. Bártková, 1993, European journal of cancer.

Distinct versus redundant properties among members of the INK4 family of cyclin‐dependent kinase inhibitors

J. Bartek, J. Lukas, J. Bártková, 2000, FEBS letters.

Induction of APOBEC3 exacerbates DNA replication stress and chromosomal instability in early breast and lung cancer evolution.

R. Harris, W. Brown, T. Fenton, 2021, Cancer discovery.

p21/WAF1/Cip1 expression in invasive ductal breast carcinoma: relationship to p53, proliferation rate, and survival at 5 years

J. Bartek, J. Bártková, M. Welcker, 2001, Virchows Archiv.

Aberrations of p16Ink4 and retinoblastoma tumour‐suppressor genes occur in distinct sub‐sets of human cancer cell lines

J. Bartek, J. Lukas, J. Bártková, 1995, International journal of cancer.

Advances in Brief DNA Damage-activated Kinase Chk 2 Is Independent of Proliferation or Differentiation Yet Correlates with Tissue Biology 1

N. Mailand, J. Bartek, J. Lukas, 2001 .

Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity.

H. Müller-Hermelink, G. Ott, J. Bartek, 1997, Blood.

Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer.

M. Strauss, B. Gusterson, J. Bartek, 1995, Cancer research.

The PRAD‐1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas

J. Bartek, J. Lukas, J. Bártková, 1994, International journal of cancer.

Expression of BCL‐2 in the developing human fetal and infant breast

B. Gusterson, J. Bártková, R. Anbazhagan, 1994, Histopathology.

Involvement of cyclin D activity in left ventricle hypertrophy in vivo and in vitro.

J. Bartek, J. Bártková, P. Busk, 2002, Cardiovascular research.

Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types.

J. Bartek, J. Lukas, G. Peters, 1995, Oncogene.

Cyclin D2 induces proliferation of cardiac myocytes and represses hypertrophy.

J. Bartek, J. Bártková, P. Busk, 2005, Experimental cell research.

The immunohistochemical expression pattern of Chk2, p53, p19INK4d, MAGE‐A4 and other selected antigens provides new evidence for the premeiotic origin of spermatocytic seminoma

J. Bartek, J. Bártková, N. Skakkebæk, 2003, Histopathology.

Autocrine VEGF – VEGFR 2 – Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth

Qiulian Wu, J. Bartek, J. Lukas, 2012 .

HLA-DR antigens on differentiating human mammary gland epithelium and breast tumours.

J. Bartek, J. Bártková, J. Kovarik, 1987, British Journal of Cancer.

Expression of CDK7/CAK in normal and tumour cells of diverse histogenesis, cell‐cycle position and differentiation

J. Bartek, J. Bártková, M. Zemanova, 1996, International journal of cancer.

Aberrant p27Kip1 promoter methylation in malignant melanoma

J. Bartek, J. Bártková, P. Guldberg, 2000, Oncogene.

First-line bevacizumab in combination with chemotherapy for HER 2-negative metastatic breast cancer : pooled and subgroup analyses of data from 2447 patients

H. Nevanlinna, J. Bartek, K. Aittomäki, 2013 .

Efficient immortalization of luminal epithelial cells from human mammary gland by introduction of simian virus 40 large tumor antigen with a recombinant retrovirus.

J. Bartek, J. Bártková, J. Taylor‐Papadimitriou, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Selective immortalization of a phenotypically distinct epithelial cell type by microinjection of SV40 DNA into cultured human milk cells

J. Bartek, J. Bártková, J. Taylor‐Papadimitriou, 1990, International journal of cancer.

Deregulation of the RB pathway in human testicular germ cell tumours

J. Bartek, J. Lukas, C. Lukas, 2003, The Journal of pathology.

Cell cycle regulators in testicular cancer: Loss of p18INK4C marks progression from carcinoma in situ to invasive germ cell tumours

N. Skakkebaek, J. Bartek, J. Bártková, 2000, International journal of cancer.

Abundance and subcellular localisation of cyclin D3 in human tumours

J. Bartek, J. Bártková, M. Zemanova, 1996, International journal of cancer.

Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin’s lymphomas. Functional studies in a cell line (Granta 519)

J. Bartek, J. Lukas, J. Bártková, 1997, Leukemia.

Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis.

J. Bartek, J. Lukas, J. Bártková, 1995, Oncogene.

Immunohtstochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies

J. Bartek, J. Lukas, J. Bártková, 1993, The Journal of pathology.

Breast development gives insights into breast disease

B. Gusterson, J. Bártková, R. Anbazhagan, 1998, Histopathology.

nvolvement of cyclin D activity in left ventricle hypertrophy in vivo and in vitro

J. Bartek, J. Bártková, P. Busk, 2001 .

Monoclonal antibody probes for p21WAF1/CIP1 and the INK4 family of cyclin-dependent kinase inhibitors.

J. Bartek, J. Lukas, J. Bártková, 2000, Hybridoma.

L. Szekely, G. Klein, J. Bartek, 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of γH2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases

H. Nevanlinna, C. Blomqvist, J. Bártková, 2022, BMC cancer.

Integrating Proteomic and Functional Genomic Technologies in Discovery-driven Translational Breast Cancer Research*

Lars Bolund, Jiri Bartek, Peter Roepstorff, 2003, Molecular & Cellular Proteomics.

The exon-junction complex helicase eIF4A3 controls cell fate via coordinated regulation of ribosome biogenesis and translational output

J. Bartek, J. Bártková, M. Lindström, 2021, Science Advances.

The development of epithelial phenotypes in the human fetal and infant breast

E. Lane, B. Gusterson, J. Bártková, 1998, The Journal of pathology.

Alcohol-abuse drug disulfiram targets cancer via p97 segregase adapter NPL4

Jiri Bartek, Klaus Kaae Andersen, Jørgen Olsen, 2017, Nature.

The retinoblastoma protein pathway and the restriction point.

J. Bartek, J. Lukas, J. Bártková, 1996, Current opinion in cell biology.

Autocrine VEGF–VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth

Jiri Bartek, Qiulian Wu, Jeremy N. Rich, 2012, The Journal of experimental medicine.

Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.

J. Bartek, J. Lukas, J. Bártková, 1991, Oncogene.

Cyclin D3: requirement for G1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation

J. Bartek, J. Lukas, J. Bártková, 1998, Oncogene.

The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.

J. Bartek, J. Lukas, J. Bártková, 1996, Cancer research.

Senescence-associated heterochromatin foci are dispensable for cellular senescence, occur in a cell type- and insult-dependent manner and follow expression of p16ink4a

J. Bartek, J. Lukas, J. Bártková, 2011, Cell cycle.

The emerging phenotype of the testicular carcinoma in situ germ cell

J. Bartek, J. Bártková, N. Skakkebæk, 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

The emerging phenotype of the testicular carcinoma in situ germ cell.

J. Bartek, J. Bártková, N. Skakkebæk, 2003 .

A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM‐3 is selectively exposed in a range of primary carcinomas

J. Bártková, J. Taylor‐Papadimitriou, C. Gillett, 1989, International journal of cancer.

Patterns of DNA damage response in intracranial germ cell tumors versus glioblastomas reflect cell of origin rather than brain environment: Implications for the anti‐tumor barrier concept and treatment

K. Křížová, J. Bartek, J. Bártková, 2014, Molecular oncology.

DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours

J. Nesland, J. Bartek, J. Lukas, 2007, Oncogene.

Deregulation of the G1/S‐phase control in human testicular germ cell tumours

J. Bartek, J. Lukas, J. Bártková, 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Chk2 tumour suppressor protein in human spermatogenesis and testicular germ-cell tumours

J. Bartek, J. Lukas, J. Bártková, 2001, Oncogene.

D‐type cyclins in adult human testis and testicular cancer: relation to cell type, proliferation, differentiation, and malignancy

Jiri Bartek, J. Bartek, J. Bártková, 1999, The Journal of pathology.

Heterochromatin marks HP1γ, HP1α and H3K9me3, and DNA damage response activation in human testis development and germ cell tumours.

J. Bartek, J. Lukas, J. Bártková, 2011, International journal of andrology.

DNA damage response in human testes and testicular germ cell tumours: biology and implications for therapy.

N. Skakkebaek, J. Bartek, J. Lukas, 2007, International journal of andrology.

Differentiation patterns of testicular germ-cell tumours as revealed by a panel of monoclonal antibodies.

J. Bartek, J. Bártková, J. Kovarik, 1987, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

Cell-cycle regulatory proteins in human wound healing.

Jiri Bartek, J. Bartek, J. Bártková, 2003, Archives of oral biology.

Human cytomegalovirus hijacks host stress response fueling replication stress and genome instability

J. Bartek, J. Bártková, A. Maya-Mendoza, 2022, Cell Death & Differentiation.

FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome

Sofia Khan, H. Nevanlinna, R. Fagerholm, 2016, International journal of cancer.

Overabundant FANCD2, alone and combined with NQO1, is a sensitive marker of adverse prognosis in breast cancer.

H. Nevanlinna, R. Fagerholm, J. Bartek, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Overabundant FANCD 2 , alone and combined with NQO 1 , is a sensitive marker of adverse prognosis in breast cancer

H. Nevanlinna, R. Fagerholm, J. Bartek, 2013 .

NQO1 expression correlates inversely with NFκB activation in human breast cancer

D. Greco, H. Nevanlinna, R. Fagerholm, 2012, Breast Cancer Research and Treatment.

MiR-34a Expression Has an Effect for Lower Risk of Metastasis and Associates with Expression Patterns Predicting Clinical Outcome in Breast Cancer

Päivi Heikkilä, Jiri Bartek, Dario Greco, 2011, PloS one.

Aberrations of the MRE11–RAD50–NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer‐predisposing gene

H. Nevanlinna, J. Bartek, J. Lukas, 2008, Molecular oncology.

NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer

Päivi Heikkilä, Jiri Bartek, Arto Mannermaa, 2008, Nature Genetics.

The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer

H. Nevanlinna, H. Eerola, J. Bartek, 2008, Oncogene.

Replication stress, DNA damage signalling, and cytomegalovirus infection in human medulloblastomas

J. Bartek, M. Svensson, G. Stragliotto, 2017, Molecular oncology.

DNA damage signalling barrier, oxidative stress and treatment‐relevant DNA repair factor alterations during progression of human prostate cancer

J. Bartek, J. Bártková, A. Burdova, 2016, Molecular oncology.

Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients

Päivi Heikkilä, Jiri Bartek, Heli Nevanlinna, 2005, International journal of cancer.

Autophagy role(s) in response to oncogenes and DNA replication stress

J. Bartek, J. Bártková, V. Gorgoulis, 2019, Cell Death & Differentiation.

Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer

J. Bartek, W. Gu, J. Bártková, 2013, Nature Cell Biology.

Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas

J. Bartek, J. Lukas, J. Bártková, 2010, Oncogene.

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

D. Adams, S. Hiddingh, H. Nevanlinna, 2010, Nature Structural &Molecular Biology.

AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity

Colin J. Daniel, S. Campello, E. Papaleo, 2021, Nature.

REV7 counteracts DNA double-strand break resection and affects PARP inhibition

Peter Bouwman, Jiri Bartek, Kees Jalink, 2015, Nature.

Myc and Ras oncogenes engage different energy metabolism programs and evoke distinct patterns of oxidative and DNA replication stress

Jiri Bartek, J. Bartek, J. Bártková, 2014, Molecular oncology.

DNA damage signalling guards against activated oncogenes and tumour progression

J. Bartek, J. Lukas, J. Bártková, 2007, Oncogene.

Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior.

Dimitris Kletsas, Jiri Bartek, Vassilis G Gorgoulis, 2007, Cancer research.

A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer

A. Trumpp, A. Bradley, R. Rad, 2015, Cell.

DNA Damage Response as an Anti-Cancer Barrier: Damage Threshold and the Concept of 'Conditional Haploinsufficiency'

J. Bartek, J. Lukas, J. Bártková, 2007, Cell cycle.

TRIP12 and UBR5 Suppress Spreading of Chromatin Ubiquitylation at Damaged Chromosomes

B. Neumann, J. Hériché, N. Mailand, 2012, Cell.

Targeting genotoxic and proteotoxic stress‐response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram

J. Bartek, J. Bártková, Z. Hodny, 2018, The Prostate.

Activation of Peroxisome Proliferator-activated Receptor γ Bypasses the Function of the Retinoblastoma Protein in Adipocyte Differentiation*

K. Kristiansen, J. Hansen, J. Bártková, 1999, The Journal of Biological Chemistry.

DNA damage response and inflammatory signaling limit the MLL-ENL-induced leukemogenesis in vivo.

J. Bartek, J. Bártková, P. Doležel, 2012, Cancer cell.

Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations

J. Bartek, P. Radice, S. Manoukian, 2011, Breast Cancer Research and Treatment.

Aberrations of the G1- and G1/S-regulating genes in human cancer.

J. Bartek, J. Lukas, J. Bártková, 1997, Progress in cell cycle research.

BCL-1/cyclin D1 oncoprotein oscillates and subverts the G1 phase control in B-cell neoplasms carrying the t(11;14) translocation.

M. Dyer, J. Bartek, J. Lukas, 1994, Oncogene.

Cyclin D1 protein expression and function in human breast cancer

Jiri Bartek, J. Bartek, J. Lukas, 1994, International journal of cancer.

CHEK2 variant I157T may be associated with increased breast cancer risk

Päivi Heikkilä, Jiri Bartek, Heli Nevanlinna, 2004, International journal of cancer.

The retinoblastoma protein pathway in cell cycle control and cancer.

J. Bartek, J. Lukas, J. Bártková, 1997, Experimental cell research.

Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint

J. Bartek, J. Lukas, J. Bártková, 1996, Molecular and cellular biology.

checkpoint . D-cyclin-dependent kinase-pRb-controlled G 1 from diverse classes of receptors at the cyclin Convergence of mitogenic signalling cascades

J. Bartek, J. Lukas, J. Bártková, 1996 .

Aberrations of the Chk2 tumour suppressor in advanced urinary bladder cancer

T. Ørntoft, J. Bartek, J. Lukas, 2004, Oncogene.

Alternative splicing and mutation status of CHEK2 in stage III breast cancer

S. Geisler, P. Lønning, A. Børresen-Dale, 2004, Oncogene.

The combined status of ATM and p53 link tumor development with therapeutic response.

M. Yaffe, M. Hemann, H. Nevanlinna, 2009, Genes & development.

DNA damage-activated kinase Chk2 is independent of proliferation or differentiation yet correlates with tissue biology.

N. Mailand, J. Bartek, J. Lukas, 2001, Cancer research.

Cancer cell stemness, responses to experimental genotoxic treatments, cytomegalovirus protein expression and DNA replication stress in pediatric medulloblastomas

J. Bartek, J. Bártková, A. Maya-Mendoza, 2020, Cell cycle.

Centrosome abnormalities are frequently observed in non‐small‐cell lung cancer and are associated with aneuploidy and cyclin E overexpression

J. Bartek, J. Bártková, C. Kittas, 2006, The Journal of pathology.

TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity

J. Bartek, J. Lukas, J. Bártková, 2016, The Journal of cell biology.

p16INK4A is a robust in vivo biomarker of cellular aging in human skin

Jiri Bartek, J. Bartek, J. Bártková, 2006, Aging cell.

Autocrine VEGF-VEGFR2—Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth

Qiulian Wu, J. Bartek, J. Lukas, 2012 .

Aberrant expression of G1-phase cell cycle regulators in flat and exophytic adenomas of the human colon.

J. Bartek, C. Rubio, E. Jaramillo, 2001, Gastroenterology.

Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage

J. Bartek, J. Lukas, C. Lukas, 2003, Nature Cell Biology.

Macrophages, Nitric Oxide and microRNAs Are Associated with DNA Damage Response Pathway and Senescence in Inflammatory Bowel Disease

Jane J. Sohn, A. Schetter, E. Bowman, 2012, PloS one.

A short acidic motif in ARF guards against mitochondrial dysfunction and melanoma susceptibility

J. Bartek, J. Bártková, P. Guldberg, 2014, Nature Communications.

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

M. Lopes, L. Wessels, J. Bartek, 2018, Cancer cell.

The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis

T. Ørntoft, C. Andersen, J. Bartek, 2013, Cell Death and Differentiation.

Distinct modes of deregulation of the proto-oncogenic Cdc25A phosphatase in human breast cancer cell lines

J. Bartek, J. Lukas, J. Bártková, 2003, Oncogene.

A high resolution genomic portrait of bladder cancer: correlation between genomic aberrations and the DNA damage response

T. Ørntoft, C. Pan, J. Bartek, 2013, Oncogene.

Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment

J. Bartek, J. Lukas, J. Bártková, 2012, Cell cycle.

JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1–mediated chromatin response to DNA breaks

B. Blagoev, J. Bartek, J. Lukas, 2013, Nature Structural &Molecular Biology.

Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress

J. Bartek, J. Bártková, R. Strauss, 2017, Oncogene.

The human nucleoporin Tpr protects cells from RNA-mediated replication stress

J. Bartek, J. Bártková, A. Maya-Mendoza, 2021, Nature Communications.

Extramedullary haematopoiesis in the human infant breast

B. Gusterson, J. Bártková, R. Anbazhagan, 1992 .

Differential expression of keratin 19 in normal human epithelial tissues revealed by monospecific monoclonal antibodies

J. Bartek, J. Bártková, J. Taylor‐Papadimitriou, 1986, The Histochemical Journal.

A series of 14 new monoclonal antibodies to keratins: Characterization and value in diagnostic histopathology

J. Bartek, J. Bártková, J. Kovarik, 1991, The Journal of pathology.

ATM Activation in Normal Human Tissues and Testicular Cancer

J. Bartek, J. Lukas, J. Bártková, 2005, Cell cycle.

The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer.

J. Bártková, R. Camplejohn, W. Gregory, 1991, British Journal of Cancer.

Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?

D M Barnes, Philip Smith, J. Bártková, 1992, European journal of cancer.

DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer

C. Swanton, J. Bartek, O. Rossanese, 2016, Genome Biology.

Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.

J. Kutok, H. Nevanlinna, J. Bartek, 2012, Human pathology.

Secretory component in differentiating normal epithelium, benign lesions and malignancy in the human breast as monitored by monoclonal antibodies

J. Bartek, J. Bártková, J. Kovarik, 2004, Histochemistry.

Keratin 19 expression in the adult and developing human mammary gland

J. Bartek, J. Bártková, J. Taylor‐Papadimitriou, 1990, The Histochemical Journal.

Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.

J. Bartek, S. Cantor, R. Beijersbergen, 2021, Molecular cell.

REV 7 counteracts DNA double-strand break resection and impacts PARP inhibition

Kees, J. Bartek, J. Bártková, 2015 .

The role of TP53 in breast cancer development.

R. Eeles, J. Bartek, J. Bártková, 1993, Cancer surveys.

Lack of beta-casein production by human breast tumours revealed by monoclonal antibodies.

J. Bartek, J. Bártková, J. Taylor‐Papadimitriou, 1987, European journal of cancer & clinical oncology.

Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ.

J. Bártková, D. Barnes, W. Gullick, 1990, Human pathology.

A panel of monoclonal antibodies to keratin no. 7: characterization and value in tumor diagnosis.

J. Bartek, J. Bártková, J. Kovarik, 1990, Neoplasma.

Long-distance inflammatory and genotoxic impact of cancer in vivo

J. Bartek, J. Bártková, M. Mistrik, 2010, Proceedings of the National Academy of Sciences.

Retinoblastoma pathway defects show differential ability to activate the constitutive DNA damage response in human tumorigenesis.

J. Bartek, J. Lukas, J. Bártková, 2006, Cancer research.

APOBEC3 as a driver of genetic intratumor heterogeneity

C. Swanton, J. Bartek, J. Bártková, 2022, Molecular & Cellular Oncology.

Monoclonal antibodies against individual cytokeratins in the detection of metastatic spread

J. Bártková, A. Rejthar, B. Vojtesek, 1988, International journal of cancer. Supplement = Journal international du cancer. Supplement.

Studies of clonal cell lines developed from primary breast cancers indicate that the ability to undergo morphogenesis IN vitro is lost early in malignancy

J. Bartek, J. Bártková, J. Taylor‐Papadimitriou, 1992, International journal of cancer.

Thresholds of replication stress signaling in cancer development and treatment

J. Bartek, J. Bártková, M. Mistrik, 2012, Nature Structural &Molecular Biology.

Use of Immunohistochemistry in Cell Cycle Studies

J. Bartek, J. Lukas, J. Bártková, 1996 .

Androgen receptor signaling fuels DNA repair and radioresistance in prostate cancer.

J. Bartek, J. Bártková, M. Mistrik, 2013, Cancer discovery.

Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer

J. Bartek, W. Gu, J. Bártková, 2013, Nature Cell Biology.

A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer

A. Trumpp, A. Bradley, R. Rad, 2015, Cell.

Loss of Nuclear DNA Ligase III Reverts PARP Inhibitor Resistance in BRCA1/53BP1 Double-deficient Cells by Exposing ssDNA Gaps

J. Bartek, S. Cantor, R. Beijersbergen, 2021, bioRxiv.

SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair

Z. Szallasi, L. Alexandrov, M. Gerlinger, 2015, Oncogene.

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

M. Lopes, L. Wessels, J. Bartek, 2019, Cancer cell.

Perspective: defects in cell cycle control and cancer.

J. Bartek, J. Lukas, J. Bártková, 1999, The Journal of pathology.

The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer.

J. Bártková, W. Gregory, M. Richards, 1991, British Journal of Cancer.

DNA damage signalling barrier, oxidative stress and treatment‐relevant DNA repair factor alterations during progression of human prostate cancer

J. Bartek, J. Bártková, A. Burdova, 2016, Molecular oncology.

DNA damage response and inflammatory signaling limit the MLL-ENL-induced leukemogenesis in vivo.

J. Bartek, J. Bártková, P. Doležel, 2012, Cancer cell.

TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity

J. Lukas, J. Bártková, A. Maya-Mendoza, 2016, The Journal of cell biology.

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

M. Lopes, L. Wessels, J. Bartek, 2018, Cancer cell.

TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity TOP BP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity

J. Lukas, J. Bártková, A. Maya-Mendoza, 2016 .

Expression of the stem cell marker CD133 in malignant meningioma.

J. Bartek, J. Bártková, H. Broholm, 2020, Clinical neuropathology.

Actionable cancer vulnerability due to translational arrest, p53 aggregation and ribosome biogenesis stress evoked by the disulfiram metabolite CuET

J. Bartek, J. Bártková, M. Lindström, 2023, Cell Death & Differentiation.

Dna Tumor Virus Oncoproteins and Retinoblastoma Gene Mutations Share the Ability to Relieve the Cell's Requirement for Cyclin D1 Function in G1

J. Lukas, J. Bártková, D. Spitkovsky, 2022 .

Androgen receptor signaling fuels DNA repair and radioresistance in prostate cancer.

J. Bartek, J. Bártková, M. Mistrik, 2013, Cancer discovery.